Complex Arrhythmia Registry

Inclusion criteria

• Patients must meet ALL of the following criteria):
• Age ≥ 18 years.
• Diagnosed with atrial fibrillation (AF), including paroxysmal AF (PAF) and persistent AF (PsAF).
• Scheduled to undergo first-time catheter ablation for AF.
• Procedure to be performed using a 3D mapping system.
• Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments.

Exclusion criteria

• Patients meeting ANY of the following criteria will be excluded):
• Severe congenital heart disease (e.g., Tetralogy of Fallot, corrected transposition of the great arteries).
• AF secondary to a clearly reversible cause (e.g., hyperthyroidism, post-operative state, acute alcohol intoxication).
• Unstable angina pectoris or acute myocardial infarction (MI) within 30 days prior to enrollment/procedure.
• Severe active infection (e.g., septic shock, sepsis).
• Contraindications to anticoagulation therapy.
• Current participation in another interventional clinical trial that may confound the results of this study.
• Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study.
• Ventricular Tachycardia (VT) Cohort
• Inclusion Criteria (Patients must meet ALL of the following criteria):
• Age ≥ 18 years.
• Diagnosed with ventricular tachycardia (VT) associated with underlying structural heart disease, including:
• Ischemic heart disease (e.g., prior MI, coronary artery disease).
• Non-ischemic cardiomyopathy (e.g., dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy (HCM)).
• Scheduled to undergo first-time catheter ablation for VT.
• Procedure to be performed using a 3D mapping system.
• Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments.
• Exclusion Criteria (Patients meeting ANY of the following criteria will be excluded):
• VT due to a transient or reversible cause (e.g., acute myocardial ischemia, severe electrolyte imbalance).
• Idiopathic ventricular tachycardia (VT occurring in the absence of structural heart disease).
• Cardiac surgery within 60 days prior to the planned ablation procedure.
• Severe coagulopathy (e.g., platelet count \< 50 x 10⁹/L, disseminated intravascular coagulation (DIC)).
• Severe heart failure with left ventricular ejection fraction (LVEF) \< 20%.
• Severe active infection (e.g., septic shock, sepsis).
• Current participation in another interventional clinical trial that may confound the results of this study.
• Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study.